aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.5030
-0.0298 (-5.59%)
At close: Aug 20, 2026, 4:00 PM EDT
0.509078
+0.0061 (1.21%)
After-hours: Aug 20, 2026, 4:00 PM EDT
aTyr Pharma Revenue
In the year 2025, aTyr Pharma had annual revenue of $190.00K, down -19.15%.
Revenue (ttm)
$190.00K
Revenue Growth
-19.15%
P/S Ratio
258.38
Revenue / Employee
$3,167
Employees
60
Market Cap
49.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 190.00K | -45.00K | -19.15% |
| Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
| Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
| Dec 31, 2022 | 10.39M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
| Dec 31, 2019 | 422.00K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 91.15M |
| Apollomics | 8.84M |
| TScan Therapeutics | 7.11M |
| Immutep | 5.28M |
| Alps Group | 3.74M |
| RenovoRx | 1.98M |
| Mereo BioPharma Group | 500.00K |
| Impact BioMedical | 35.00K |
ATYR News
- 1 day ago - Ethos to Present at the Goldman Sachs Communacopia + Technology Conference - GlobeNewsWire
- 7 days ago - Ethos Signs Erin Andrews as Its Next Sports Partner in Growing Campaign to Make Life Insurance Accessible for Every Family - GlobeNewsWire
- 13 days ago - aTyr Pharma reports Q2 EPS (11c), consensus (13c) - TheFly
- 13 days ago - aTyr Pharma announces restructuring, will lay off roughly 60% of workforce - TheFly
- 13 days ago - aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD - GlobeNewsWire
- 13 days ago - aTyr Pharma Quarterly report: Q2 2026 - Filings
- 13 days ago - aTyr Pharma Earnings release: Q2 2026 - Filings
- 17 days ago - Ethos Reports Second Quarter Fiscal Year 2026 Financial Results - GlobeNewsWire